|Last Price$36.68||Day Change (%)-2.46%|
|Open Price$37.33||Day Change ($)-0.92|
|Day Range36.20–37.55||52-Week Range33.16–110.75|
As of Fri 10/21/2016 5:00:00 PM | USD
Paroxysmal Nocturnal Hemoglobinuria Pipeline Review, H2 2016 - Research and Markets
Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.
Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.